| P50 | author | Michael J Rybak | Q106082725 |
| P2093 | author name string | Céline Vidaillac | |
| P2860 | cites work | Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin | Q42112713 |
| | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections | Q42444666 |
| | Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. | Q42584480 |
| | Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates | Q42747697 |
| | Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus | Q43183402 |
| | BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials | Q43895628 |
| | Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci | Q44655200 |
| | In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria | Q44755053 |
| | Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates | Q45068054 |
| | Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration | Q46435928 |
| | Incidence, antibiotic resistance and clonal relations of MRSA strains isolated from a Romanian university hospital | Q46572231 |
| | In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study | Q46667305 |
| | Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). | Q46667419 |
| | A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections | Q46787486 |
| | In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin | Q46792584 |
| | Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. | Q46878727 |
| | Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis | Q46904137 |
| | In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci | Q24550612 |
| | Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus | Q33935282 |
| | Methicillin resistance in Staphylococcus aureus: mechanisms and modulation | Q34124916 |
| | In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci | Q34162130 |
| | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae | Q34624359 |
| | In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals | Q34973784 |
| | PBP 2a mutations producing very-high-level resistance to beta-lactams | Q35547377 |
| | Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects | Q35879080 |
| | Ceftobiprole: in-vivo profile of a bactericidal cephalosporin | Q36416472 |
| | Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains | Q36744877 |
| | Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy | Q36763997 |
| | In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus | Q36815290 |
| | Analysis of cephalosporin antibiotics | Q36906409 |
| | In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models | Q36932924 |
| | Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity | Q37030780 |
| | Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia | Q37119259 |
| | Pharmacokinetic and pharmacodynamic profile of ceftobiprole. | Q37126977 |
| | The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials | Q37126984 |
| | Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains | Q37156698 |
| | Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. | Q37733667 |
| | In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus | Q38899451 |
| | In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections | Q39077347 |
| | Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms | Q39077719 |
| | BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis | Q39650937 |
| | In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters | Q39652995 |
| | Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers | Q40967997 |
| | Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers | Q40968003 |
| | Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus | Q41092910 |
| | Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus | Q41336401 |
| | Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. | Q41473443 |
| | Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin | Q41847350 |
| | Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes | Q42107999 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| | methicillin-resistant Staphylococcus aureus | Q595158 |
| P304 | page(s) | 511-525 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus | |
| P478 | volume | 29 | |